Literature DB >> 22351251

Is HER2 overexpression sufficient for optimal response to Pertuzumab?

Mehmet Ali Nahit Sendur, Sercan Aksoy, Sebnem Yaman, Nuriye Yıldırım Özdemir, Nurullah Zengin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22351251     DOI： 10.1007/s12032-012-0183-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  9 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Authors:  Camellia W Adams; David E Allison; Kelly Flagella; Leonard Presta; Janet Clarke; Noel Dybdal; Kathleen McKeever; Mark X Sliwkowski
Journal:  Cancer Immunol Immunother       Date:  2005-09-03       Impact factor: 6.968

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.

Authors:  Connie G Chiu; Hamid Masoudi; Samuel Leung; David K Voduc; Blake Gilks; David G Huntsman; Sam M Wiseman
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

5.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

Authors:  Anjali Naresh; Weiwen Long; Gregory A Vidal; William C Wimley; Luis Marrero; Carolyn I Sartor; Sian Tovey; Timothy G Cooke; John M S Bartlett; Frank E Jones
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

7.  Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Authors:  Sharmila Makhija; Lukas C Amler; Dana Glenn; Frederick R Ueland; Michael A Gold; Don S Dizon; Virginia Paton; Chin-Yu Lin; Thomas Januario; Kimmie Ng; Andreas Strauss; Stephen Kelsey; Mark X Sliwkowski; Ursula Matulonis
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

Review 8.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Authors:  Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2009-04-03

9.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.